Profile data is unavailable for this security.
About the company
Lupin Limited is an India-based innovation-led transnational pharmaceutical company. The Company develops and commercializes a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The Company has a presence in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and others. Its complex generics portfolio includes Filgrastim, Pegfilgrastim, Etanercept and Albuterol and others. Its biosimilar products include Lupifil (Filgrastim), Lupifil-P (Peg-Filgrastim) and Etanercept. Its diabetes brands include ONDERO and ONDERO MET. The Company has 15 manufacturing sites, seven research centers, and more than 20,000 professionals working globally.
- Revenue in INR (TTM)200.11bn
- Net income in INR19.14bn
- Incorporated1983
- Employees20.79k
- LocationLupin LtdB/4 Laxmi Towers, Bandra Kurla Complex, Bandra (E)MUMBAI 400055IndiaIND
- Phone+91 2 266402323
- Fax+91 2 266402051
- Websitehttps://www.lupin.com/
More ▼
Mergers & acquisitions
| Acquired company | LUPIN:NSI since announced | Transaction value |
|---|---|---|
| A Menarini India Pvt Ltd | 60.40% | 12.15m |
| A Menarini Asia-Pacific Holdings Pte Ltd | 60.40% | -- |
Data delayed at least 15 minutes, as of Jul 22 2024 11:16 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals Limited | 34.54bn | 5.90bn | 434.30bn | 3.21k | 73.62 | 24.43 | 65.84 | 12.57 | 34.82 | 34.82 | 203.88 | 104.93 | 1.00 | 2.71 | 16.67 | 10,755,860.00 | 17.14 | 11.01 | 29.26 | 17.88 | 61.36 | 55.77 | 17.08 | 12.25 | 1.49 | 466.45 | 0.0104 | 192.07 | 6.21 | 2.00 | -2.91 | 5.78 | -36.02 | 9.86 |
| Abbott India Ltd | 58.49bn | 12.01bn | 611.89bn | 3.81k | 50.94 | 16.54 | 48.09 | 10.46 | 565.30 | 565.30 | 2,752.52 | 1,740.71 | 1.20 | 4.96 | 17.09 | 15,335,370.00 | 24.64 | 20.92 | 33.37 | 28.59 | 44.94 | 44.20 | 20.54 | 17.26 | 1.94 | 111.00 | 0.022 | 77.06 | 9.35 | 9.72 | 26.52 | 21.68 | 31.08 | 52.32 |
| Alkem Laboratories Ltd | 126.68bn | 17.96bn | 630.44bn | 16.87k | 35.11 | 6.11 | 29.87 | 4.98 | 150.19 | 150.19 | 1,059.44 | 862.57 | 0.8638 | 1.87 | 5.78 | -- | 12.35 | 11.88 | 17.39 | 17.50 | 61.02 | 59.43 | 14.30 | 13.94 | 1.94 | 8.32 | 0.1169 | 25.80 | 9.21 | 11.48 | 82.47 | 18.75 | -13.30 | 20.11 |
| Aurobindo Pharma Ltd | 290.02bn | 31.73bn | 783.05bn | 15.69k | 24.69 | 2.62 | 16.69 | 2.70 | 54.12 | 54.12 | 494.54 | 509.35 | 0.6827 | 1.38 | 6.25 | -- | 7.46 | 9.24 | 10.35 | 13.43 | 56.54 | 54.15 | 10.93 | 12.72 | 1.18 | 16.12 | 0.1821 | -- | 16.68 | 8.19 | 64.62 | 6.06 | 17.96 | -- |
| Lupin Ltd | 200.11bn | 19.14bn | 828.59bn | 20.79k | 43.39 | 5.79 | 28.27 | 4.14 | 41.88 | 41.88 | 437.77 | 313.60 | 0.8524 | 1.35 | 4.36 | 9,625,677.00 | 8.24 | 1.43 | 13.34 | 2.22 | 66.82 | 58.52 | 9.67 | 2.04 | 0.9702 | 9.18 | 0.1689 | 75.03 | 20.25 | 6.41 | 345.15 | 30.18 | -1.17 | 9.86 |
| Mankind Pharma Ltd | 103.35bn | 19.13bn | 856.90bn | 19.54k | 44.85 | 9.15 | 36.62 | 8.29 | 47.69 | 47.69 | 257.67 | 233.73 | -- | -- | -- | 5,289,035.00 | -- | -- | -- | -- | 68.94 | -- | 18.79 | -- | 2.35 | -- | 0.0212 | -- | 18.12 | -- | 49.23 | -- | -- | -- |
| Torrent Pharmaceuticals Ltd | 107.28bn | 16.56bn | 1.04tn | 14.92k | 62.49 | 15.10 | 42.22 | 9.65 | 48.94 | 48.94 | 316.97 | 202.58 | 0.7135 | 1.19 | 5.66 | 7,192,170.00 | 11.02 | 8.34 | 17.25 | 13.03 | 74.96 | 71.78 | 15.44 | 13.18 | 0.6142 | 7.24 | 0.3697 | 61.65 | 11.51 | 6.93 | 33.02 | 30.58 | -8.17 | 26.93 |
| Dr Reddy's Laboratories Ltd | 280.11bn | 55.78bn | 1.11tn | 26.34k | 19.93 | 3.93 | 15.76 | 3.96 | 334.60 | 334.60 | 1,680.26 | 1,696.70 | 0.7874 | 1.46 | 3.67 | 10,633,220.00 | 15.68 | 11.37 | 21.05 | 16.02 | 70.69 | 65.86 | 19.91 | 14.63 | 1.92 | 41.28 | 0.0662 | 15.91 | 13.54 | 12.64 | 23.75 | 23.39 | 26.78 | 14.87 |
| Zydus Lifesciences Ltd | 195.47bn | 38.37bn | 1.19tn | 26.24k | 31.27 | 6.02 | 25.96 | 6.10 | 37.91 | 38.14 | 193.17 | 197.07 | 0.7103 | 1.74 | 4.05 | 7,449,467.00 | 13.92 | 9.05 | 19.29 | 14.01 | 68.14 | 61.15 | 19.60 | 14.33 | 1.48 | -- | 0.0351 | 16.48 | 13.40 | 8.23 | 95.25 | 15.72 | -3.03 | -3.04 |
| Cipla Ltd | 257.74bn | 41.22bn | 1.22tn | 26.62k | 29.53 | 4.55 | 23.37 | 4.72 | 51.02 | 51.02 | 319.08 | 330.77 | 0.829 | 1.70 | 5.84 | -- | 13.37 | 10.09 | 16.16 | 12.40 | 65.78 | 59.69 | 16.12 | 12.66 | 2.71 | 58.30 | 0.0205 | 20.79 | 13.28 | 9.51 | 47.10 | 21.96 | 20.68 | 34.08 |
| Divi's Laboratories Ltd | 78.45bn | 16.00bn | 1.22tn | 17.50k | 76.08 | 8.97 | 61.53 | 15.51 | 60.26 | 60.26 | 295.51 | 511.21 | 0.5246 | 0.999 | 3.97 | 4,482,857.00 | 10.70 | 16.55 | 11.62 | 18.22 | 60.11 | 56.24 | 20.40 | 26.38 | 5.02 | -- | 0.0002 | 34.32 | 0.9976 | 9.66 | -12.25 | 3.41 | 6.47 | 13.40 |
Data as of Jul 22 2024. Currency figures normalised to Lupin Ltd's reporting currency: Indian Rupee INR
28.19%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Sep 2023 | 37.49m | 8.22% |
| ICICI Prudential Asset Management Co. Ltd.as of 30 Sep 2023 | 23.39m | 5.13% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 30 Sep 2023 | 16.73m | 3.67% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 9.04m | 1.98% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 30 Jun 2024 | 8.59m | 1.89% |
| HDFC Life Insurance Co. Ltd. (Investment Portfolio)as of 30 Sep 2023 | 7.66m | 1.68% |
| Mirae Asset Investment Managers (India) Pvt Ltd.as of 30 Sep 2023 | 7.66m | 1.68% |
| BlackRock Fund Advisorsas of 04 Jul 2024 | 6.36m | 1.40% |
| Norges Bank Investment Managementas of 30 Sep 2023 | 6.27m | 1.38% |
| SBI Funds Management Ltd.as of 30 Jun 2024 | 5.33m | 1.17% |
More ▼
Data from 31 Dec 2023 - 18 Jul 2024Source: FactSet Research Systems Inc.
